Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00939848

Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers (ABC-03)

Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers

Sponsor: AstraZeneca

Conditions Biliary Tract Neoplasms

Interventions Placebo cediranib cisplatin gemcitabine

Updated 5 times since 2017 Last updated: Oct 24, 2014 Started: Apr 30, 2011 Primary completion: Sep 30, 2012 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00939848, this PHASE2/PHASE3 trial focuses on Biliary Tract Neoplasms and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University College, London

Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom
• Manchester, United Kingdom